Berkeley Immune Support Formula Logo (Diindolylmethane DIM Natural Immune Booster)
  • Powerful Natural Immune Booster
    Bioavailable Nutrient Delivery System

  • Diindolylmethane (DIM)
    Imune, Breast, Prostate, Colon & Skin Health

  • Sulforaphane
    Cellular Detoxification

  • Selenium
    Immune, Breast, Prostate & Vision Health

  • Lycopene
    Cardiovascular, Breast & Prostate Health

  • Lutein
    Immune, Vision & Prostate Health

  • Zeaxanthin
    Vision Health

  • Vitamins C, D3 and E
    Immune Support & Bone Health

  • Citrus Bioflavonoids
    Immune & Cardiovascular Health

Diindolylmethane DIM Natural Immune System Booster

  

broccoli flowers

 

Sign Up for Our Free

Newsletter and Promotions

 

buy now button

 

Order Online or Call

US Toll-Free

1-877-777-0719

Customer Service Available Mon-Fri 9-5 (US Pacific Time)

  

Savings With

Membership

Programs

 

Money Back

Guarantee

share this button

 

ABOUT - Born from Nature. Powered by Berkeley.

 

The Berkeley Immune Support Formula is an all natural immune enhancing dietary supplement featuring proprietary technology exclusively developed by Berkeley BioSciences, Inc.

 

Berkeley BioSciences Scientific Advisory Board

 

Dr. Leonard Bjeldanes, Ph.D., is Professor and former Chairman of the Nutritional Sciences Department at the University of California at Berkeley. Dr. Bjeldanes' laboratory is recognized globally for its innovations in the fields of nutrition and molecular oncology and is particularly credited for its pioneering research on Diindolylmethane (DIM). Dr. Bjeldanes' laboratory was the first to discover DIM's anti-proliferative effects on prostate cancer cells and discover its biological mechanism of action, the first to discover DIM's role in healthy estrogen metabolism, the first to discover DIM's multitude of anti-proliferative effects on human mammary tumor cells, and more recently, the first laboratory to discover DIM's unique immune modulatory properties. This recent discovery helps to shed light on important biomedical questions regarding DIM's effect on RRP tumors and Cervical Dysplasia. It has opened new vistas for biomedical investigators worldwide and has led to a global effort to leverage this unique mode of action for a multitude of diseases: from AIDS, Hepatitis, and Human Papilloma Virus to most forms of cancer. Dr. Bjeldanes has authored over 100 publications in prominent scientific journals and is the inventor of numerous issued and pending patents in the fields of molecular immunology and oncology, including the patent on the use of DIM for immune modulation exclusively licensed by Berkeley BioSciences, Inc. Dr. Bjeldanes is a member of the American Chemical Society, American Association for the Advancement of Science, American Institute of Nutrition and the Society of Toxicology. He has served on the Editorial Boards of the Journal of Nutrition, Journal of Toxicology and Environmental Health, Food Research International and Chemical Research in Toxicology. Dr. Bjeldanes is a co-founder of Berkeley BioSciences, Inc. and a member of its Scientific Advisory Board.

 

Dr. Gary Firestone, Ph.D., is Director of the National Institutes of Health Cancer Research Program, Professor of Molecular and Cell Biology, and former Chairman of the College of Letters and Science at the University of California at Berkeley. He is an internationally recognized scientist in the field of molecular oncology and a highly sought after speaker at scientific conferences on oncology research. His laboratory is also recognized for its pioneering work on Diindolylmethane. Dr. Firestone's laboratory, in collaboration Dr. Bjeldanes', was the first in the world to conduct a human clinical study on Diindolylmethane supplementation and demonstrate that it increased the 2-hydroxylation of estrogen metabolites--a biological activity that in a large scale clinical trial has been shown to be linked to a lower risk of breast cancer. Together, Dr. Firestone and Dr. Bjeldanes as a team have published more scientific papers on Diindolymethane than any other scientific team worldwide. Dr. Firestone has published over 100 publications in prominent scientific journals and is the inventor of multiple issued and pending patents in the fields of molecular immunology and oncology. He is a co-inventor on the patent regarding the use of DIM for immune modulation exclusively licensed by Berkeley BioSciences, Inc. Dr. Firestone has served on the Editorial Boards of the Journal of Molecular Endocrinology and the Journal of Experimental Zoology in addition to serving on the grant review boards of the National Science Foundation and the National Institutes of Health. He is a member of the American Society of Cell Biology, American Association of Cancer Research and the American Association for the Advancement of Science. Dr. Firestone is a co-founder of Berkeley BioSciences, Inc. and a member of its Scientific Advisory Board.

Dr. Christopher Benz, M.D., is Professor of Medicine in Oncology at the University of California San Francisco School of Medicine and Program Director of the Cancer and Developmental Therapeutics Program at the Buck Institute for Research on Aging. He is an internationally recognized scientist in cancer research. When he joined the UCSF Medical Center in 1983, he established the very first laboratory at UCSF focused on breast cancer research. He is a practicing oncologist at the UCSF Carol Franc Buck Breast Care Center, senior member of the UCSF Cancer Center Breast Oncology Program, faculty member in the UCSF-UC Berkeley Graduate Program of Bioengineering, and a member of the American Association for Cancer Research International Aging Taskforce. Dr. Benz is a key participant in the interdisciplinary team of Buck Institute geroscientists actively collaborating to better understand and prevent age-associated illnesses like cancer. A primary goal of Dr. Benz's research has been to understand the link between aging and cancer: why the incidence of cancer increases with age, how the biology of cancer is impacted by normal aging, and how to use this information to improve cancer prevention and treatment. The Benz laboratory at the Buck Institute focuses on several clinical types of breast cancer including those that over-express the estrogen receptor (ER), an age-associated mechanism that drives the most rapidly increasing form of breast cancer worldwide. Dr. Benz has published over 100 publications in prominent scientific journals and actively collaborates with the laboratories of Dr. Bjeldanes and Dr. Firestone at UC Berkeley in the research of Diindolylmethane as a natural therapeutic for multiple forms of cancer, including breast cancer. Dr. Benz is a member of the Scientific Advisory Board of Berkeley BioSciences, Inc.

Dr. Warner Greene, M.D., Ph.D., is Professor of Medicine in Microbiology and Immunology at the University of California San Francisco School of Medicine and Director of the Gladstone Institute of Virology and Immunology at UCSF where he oversees the Institute's vast biomedical research activities in the fields of immunology and virology. Regarded as one of the leading figures in the field of immunology, he is a highly sought after speaker in international biomedical conferences on immunology and immune related diseases. Dr. Greene's laboratory focuses on the pathogenic interplay of the HIV-1 and HTLV-I human retroviruses with immune cells. Infection of human hosts with these retroviruses produces contrasting diseases within the CD4 subset of T lymphocytes, specifically the Acquired Immune Deficiency Syndrome (AIDS) with HIV-1 and the Adult T-Cell Leukemia (ATL) with HTLV-1. His laboratory specializes in exploring the molecular biology of these conditions in addition to studying the role that Nuclear Factor Kappa Beta (NFkB) plays in inflammatory responses and how a regulation of NFkB activity may affect different disease conditions. Dr. Greene has published over 100 publications in prominent scientific journals and is a Fellow of the American Academy for the Advancement of Science. He is a member of the Executive Board of the AIDS Research Institute at UCSF and the Institute of Medicine of the United States National Academy of Sciences. Dr. Greene is a clinical immunologist at the UCSF Medical Center and is actively collaborating with the laboratories of Dr. Bjeldanes and Dr. Firestone at UC Berkeley in the research of Diindolylmethane as a natural therapeutic for multiple forms of infectious disease and cancer, including AIDS and Leukemia. Dr. Greene is a member of the Scientific Advisory Board of Berkeley BioSciences, Inc.

Dr. Giuseppe Del Priore, M.D., M.P.H. is Professor of Medicine and Director of Gynecologic Oncology at the Indiana University School of Medicine. Dr. Del Priore led the first human clinical trials of Diindolylmethane for the treatment of cervical dysplasia caused by the HPV virus. Prior to joining the faculty at Indiana University School of Medicine, Dr. Del Priore was the Vice President of Research at the New York University Downtown Hospital where he supervised the clinical trials of Diindolylmethane within HPV patients. Dr. Del Priore's current research efforts continue to focus on the development of Diindolylmethane as a naturally occurring therapeutic candidate for a variety of conditions. An active area of research in his laboratory involves the prevention of HPV infection and early treatment of the disease. Cervical dysplasia caused by HPV is currently the leading cause of cervical cancer in women worldwide. Addressing cervical dysplasia early on can significantly impact the occurrence of cervical cancer worldwide. Dr. Del Priore is an Honorary member of the European Society of Gynecologic Oncology and Consultant at the Chelsea and Westminster Hospital, National Health Service, London-- only one of two physicians ever to hold that honorary position. Dr. Del Priore is a member of the Scientific Advisory Board of Berkeley BioSciences, Inc.

Mission

 

Berkeley BioSciences Inc. is dedicated to helping people lead healthier lives through the development of first-in-class nutrition and healthcare products based on rigorous scientific research and proprietary knowledge. The company has two divisions: nutraceutical and biopharmaceutical. The nutraceutical division markets the Berkeley Immune Support Formula and the biopharmaceutical division is researching and developing nature-based therapeutics for multiple forms of cancer (breast, prostate, lung, colon, cervical) and infectious diseases (AIDS, SARS, Hepatitis, HPV, Influenza, Pandemic Flu).

 

Contact

 

To contact us, please write to:

Berkeley Immune Support Formula

Customer Service Mail Center
1434 Westwood Blvd. # 5
Los Angeles, CA 90024

Customer Service Telephone: US Toll-Free 1-877-777-0719

  • Powerful Natural Immune Booster
    Bioavailable Nutrient Delivery System

  • Diindolylmethane (DIM)
    Immune, Breast, Prostate, Colon & Skin Health

  • Sulforaphane
    Cellular Detoxification

  • Selenium
    Immune, Breast, Prostate & Vision Health

  • Lycopene
    Cardiovascular, Breast & Prostate Health

  • Lutein
    Immune, Vision & Prostate Health

  • Zeaxanthin
    Vision Health

  • Vitamins C, D3 and E
    Immune Support & Bone Health

  • Citrus Bioflavonoids
    Immune & Cardiovascular Health

 

 

 

 

 

 

Note to Consumers

 

The Berkeley Immune Support Formula is a nutritional supplement. Statements made on this website have not been evaluated by the US Food and Drug administration. The product featured is not intended to diagnose, treat, cure or prevent any disease. For medical advice please contact a licensed healthcare professional.

 

Home ı Science ı Product ı Purchase ı FAQ ı News ı About

Español ı Guarantee ı Legal Notices ı Privacy

 

2007-2017 Berkeley BioSciences, Inc.